38 results about "Management of Parkinson's disease" patented technology

A statistical and functional correlation strategy to identify changes in cellular pathways specifically linked to impaired cognitive function with aging. Analyses using the strategy identified multiple groups of genes expressed in the hippocampi of mammals, where the genes were expressed at different levels for several ages. The aging changes in expression began before mid-life. Many of the genes were involved in specific neuronal and glial pathways with previously unrecognized relationships to aging and/or cognitive decline. The processes identified by the strategy suggest a new hypothesis of brain aging in which initially decreased neuronal activity and/or oxidative metabolism trigger separate but parallel genomic cascades in neurons and glia. In neurons, the cascade results in elevations in calcium signaling and reductions of immediate early gene signaling, biosynthesis, synaptogenesis and neurite remodeling. In contrast, glia undergo increased lipid metabolism and mediate a cycle of demyelination and remyelination that induces antigen presentation, inflammation, oxidative stress and extracellular restructuring. These identified genes and the proteins they encode can be used as novel biomarkers of brain aging and as targets for developing treatment methods against age-related cognitive decline, Alzheimer's Disease and Parkinson's Disease.

The invention provides improved agents and methods for treatment of diseases associated with synucleinopathic diseases, including Lewy bodies of alpha-synuclein in the brain of a patient. Such methods entail administering agents that induce a beneficial immunogenic response against the Lewy body. The methods are particularly useful for prophylactic and therapeutic treatment of Parkinson's disease.

Various embodiments of the present invention describe mechanisms configured to monitor, track, and manage symptoms of Parkinson's disease (PD). According to particular exemplary embodiments, a system includes sensors configured to monitor motion exhibited by a user having symptoms of Parkinson's disease, a processor configured to determine whether the motion constitutes a tremor episode, and memory configured to maintain data associated with the tremor episode, a severity rating associated with the tremor episode, and medication intake information. In exemplary embodiments, the effectiveness of a user's medication intake can be determined based on data displayed regarding severity rating variations over time in relation to medication intake.

A liquid aqueous formulation for the intranasal administration of apomorphine includes:

• • (a) at least about 15 mg/ml of apomorphine; and
  • (b) a solubilising agent selected from
    • (i) at least one polyoxyethylene-polyoxypropylene copolymer (poloxamer);
    • (ii) at least one cyclodextrin; and
    • (iii) at least one cyclodextrin together with chitosan.

The formulations of the invention can be used in the treatment or management of Parkinson's disease and erectile dysfunction.

The invention particularly relates to a week-acting transdermal pramipexole patch and a preparation method thereof, and belongs to the field of pharmaceutic preparations. The week-acting transdermal pramipexole patch comprises a medicament storage bin, an anti-adhesion layer and a back lining layer. A double-layer patch is prepared by mixing a hydrophilic matrix with a penetration enhancer and adopting a laminated pouring method, so that the problems in multi-layer film preparation are effectively solved; furthermore, constant-speed release of a medicament within seven days can be guaranteed. An animal experiment shows that the week-acting transdermal pramipexole patch is non-irritative and non-allergenic to the skin. The patch disclosed by the invention has the advantages of definite treating effect, stable quality, high safety and convenience in use and is used for treating parkinsoncs disease.

The invention belongs to the field of biological medicine and specifically relates to a neural stem cell preparation for treating a Parkinson's disease through nasal delivery as well as a preparation method and application thereof. The preparation method comprises the following steps: cultivation and purification of seed cells; cultivation of P6-P8 generation cells; cultivation of a working cell repository; preparation of a preparation for treating the Parkinson's disease. According to the preparation as well as the preparation method and the application thereof, after the preparation is dropped or injected into a nasal cavity, the preparation can quickly form a solid membrane shape under a body temperature condition and can be adsorbed on the nasal cavity for slow absorption, and the preparation cannot enter an oral cavity or lungs along with breathing, so that the preparation can be used by patients and doctors conveniently and fast; in addition, test data indicate that the preparation has better curative effect and safety compared with a traumatic corpus striatum delivery. The preparation can be used for treating the Parkinson's disease, and an immunosuppressive agent is not needed.

The present invention is directed to methods of treating movement disorders by administering an effective amount of one or more adenosine A_2A receptor antagonists to a patient in need thereof. The present invention also provides methods of decreasing the adverse effects of L-DOPA in patients receiving L-DOPA therapy in the treatment of Parkinson's disease. The present invention further provides methods and compositions for treating Parkinson's disease patients with sub-clinically effective doses of L-DOPA by combining L-DOPA treatment with an effective amount of one or more adenosine A_2A receptor antagonists (i.e., L-DOPA sparing effect). The present invention further provides methods of effective treatment of Parkinson's disease by co-administering at least one adenosine A_2A receptor antagonist, L-DOPA and a dopamine agonist and/or a COMT inhibitor and/or a MAO inhibitor. The present invention further provides methods of prolonging effective treatment of Parkinson's disease by administering an adenosine A_2A receptor antagonist singly or together with a dopamine agonist, and/or a COMT inhibitor, and/or a MAO inhibitor without prior or subsequent administration of L-DOPA, delaying or removing on-set of L-DOPA motor complication.

A method of treating Parkinson's Disease in patients exhibiting increasing resistance to the administration of L-dopa due to loss of aromatic L-amino acid decarboxylic activity in striatal neurons comprises transfection of the caudate and/or putamen regions with a viral vector encoding AADC. The vector preferably has a promoter system provided for the expression of the AADC nucleic acid, and is injected at a slow rate, at a level designed to restore AADC activity to tissues undergoing progressive loss of that activity. The AADC renewed activity permits conversion of L-dopa, in the brain, to dopamine.

An application of oroxylin A and a pro-drug thereof as a catechol-type medicine synergist belongs to the technical field of medicines. The compound is used as the catechol-type medicine synergist and has the following structure general formula (I), wherein R is hydrogen, carboxylic ester, glucuronic acid and the like substitutive groups. One or more compounds of the oroxylin A and the pro-drug thereof can be mixed with levodopa according to a certain ratio to prepare a drug composition for treatment of Parkinson's disease. The oroxylin A and the pro-drug prepared through modification thereof are improved in both solubility and transmembrane capability and are significantly prolonged in in-vivo metabolic half life period, which is longer than the in-vivo metabolic half life periods of majority of catechol-type medicines, so that the compounds have excellent medicine preparation prospect. In addition, the compounds also can be combined with a catechol-type medicine to form a compound medicine. The compound medicine can be prepared into an oral-taking slow-release preparation to further improve oral-taking bioavailability and treatment effects of the catechol-type medicines.

Disclosed are compounds having the structure of Formula I, or a pharmaceutically acceptable salt of any thereof: wherein: “Z” and R1 are defined herein, which compounds are believed suitable for use in selectively antagonizing the A2a receptors, for example, those found in high density in the basal ganglia. Such compounds and pharmaceutical formulations are believed to be useful in treatment or management of neurodegenerative diseases, for example, Parkinson's disease, or movement disorders arising from use of certain medications used in the treatment or management of Parkinson's disease.

Described herein are compositions and methods for the treatment of Parkinson's disease (PD) and/or to protect dopaminergic nigrostriatal neuronal cell bodies from 6-OHDA-induced neurotoxicity in a mammal. In various embodiments of the invention, the dopaminergic neuron differentiation factor sonic hedgehog (Shh) and/or its downstream transcription factor target Gli-1 are used in connection with gene therapeutic techniques or direct peptide injection for the aforementioned indications. Kits useful in practicing the inventive method are also disclosed, as are animal models useful for studying various neurodegenerative conditions.

The invention belongs to the technical field of medicine, discloses an application of U0126 in preparation of a PD (Parkinson's disease) treatment drug and particularly provides an application of the U0126 in preparation of a drug for delaying dopaminergic neuron degeneration. A product can effectively delay degenerative death of dopaminergic neurons, and the PD is treated fundamentally; the treatment effect of the drug can be realized through oral administration instead of injection, and the drug has a better curative effect on PD caused by various reasons and has great significance on treatment and healing of PD.

The scheme of the invention discloses a medical composition for treating Parkinson 's disease in the field of treatment medicines for the Parkinson 's disease. The medical composition consists of thefollowing active components in parts by weight of 5-20 parts of aspirin and 10-40 parts of levodopa. According to the medical composition disclosed by the invention, the aspirin and the levodopa are united to prevent and treat the Parkinson 's disease, the levodopa can alleviate symptoms of shaking palsy and improve muscular tension, besides, the synergistic reaction of medicines is exerted, dopaminergic neuron can be protected, the treatment scheme has precise treatment effects on the Parkinson 's disease, and besides, side effects caused by medicines in the treatment course of the Parkinson's disease can be notably reduced.

The invention relates to the compounds of formula I, formula II and/or formula III or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compound of formula I, formula II or formula III, and methods for treating or preventing Parkinson's disease may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, subcutaneous, depot, intramuscular, syrup, or injection. Such compositions may be used to treatment or management of Parkinson's disease as well as scleroderma, restless leg syndrome, hypertension and gestational hypertension.

The invention relates to a treatment effect of a monoclonal antibody on Parkinson's disease, wherein the monoclonal antibody is an anti-serine 129 site phosphorylated alpha synuclein (p-alpha-synuclein, p-alpha-syn) monoclonal antibody (C140S). The invention particularly relates to an effect research of the antibody in treatment of abnormal activation of immune cells.

Disclosed are compounds having the structure of Formula I, or a pharmaceutically acceptable salt of any thereof, wherein: “Z”, R¹ and R² are defined herein, which compounds are believed suitable for use in selectively antagonizing the A2a receptors, for example, those found in high density in the basal ganglia. Such compounds and pharmaceutical formulations are believed to be useful in treatment or management of neurodegenerative diseases, for example, Parkinson's disease, or movement disorders arising from use of certain medications used in the treatment or management of Parkinson's disease.

Uses of n-butylidenephthalide (BP) in dopaminergic progenitor cell transplantation are provided, wherein the uses include using BP to enhance the therapeutic effect of dopaminergic progenitor cell transplantation, and using a combination of BP and BP-treated dopaminergic progenitor cells in dopaminergic progenitor cell transplantation. The uses especially relate to using BP to enhance the therapeutic effect of dopaminergic progenitor cell transplantation on Parkinson's disease.

The invention belongs to the technical field of medicine, discloses an application of PD0325901 in preparation of a PD (Parkinson's disease) treatment drug and particularly provides an application of the PD0325901 in preparation of a drug for delaying dopaminergic neuron degeneration. A product can effectively delay degenerative death of dopaminergic neurons, and the PD is treated fundamentally; the treatment effect of the drug can be realized through oral administration instead of injection, and the drug has a better curative effect on PD caused by various reasons and has great significance on treatment and healing of PD.